JP2022550899A5 - - Google Patents

Info

Publication number
JP2022550899A5
JP2022550899A5 JP2022520797A JP2022520797A JP2022550899A5 JP 2022550899 A5 JP2022550899 A5 JP 2022550899A5 JP 2022520797 A JP2022520797 A JP 2022520797A JP 2022520797 A JP2022520797 A JP 2022520797A JP 2022550899 A5 JP2022550899 A5 JP 2022550899A5
Authority
JP
Japan
Prior art keywords
cells
receptor
derived
cell
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550899A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/054601 external-priority patent/WO2021071962A1/en
Publication of JP2022550899A publication Critical patent/JP2022550899A/ja
Publication of JP2022550899A5 publication Critical patent/JP2022550899A5/ja
Pending legal-status Critical Current

Links

JP2022520797A 2019-10-07 2020-10-07 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 Pending JP2022550899A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962912000P 2019-10-07 2019-10-07
US62/912,000 2019-10-07
US201962916468P 2019-10-17 2019-10-17
US62/916,468 2019-10-17
PCT/US2020/054601 WO2021071962A1 (en) 2019-10-07 2020-10-07 Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof

Publications (2)

Publication Number Publication Date
JP2022550899A JP2022550899A (ja) 2022-12-05
JP2022550899A5 true JP2022550899A5 (enExample) 2023-10-17

Family

ID=75437509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520797A Pending JP2022550899A (ja) 2019-10-07 2020-10-07 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用

Country Status (11)

Country Link
US (1) US20240115602A1 (enExample)
EP (1) EP4041759A4 (enExample)
JP (1) JP2022550899A (enExample)
KR (1) KR20220108038A (enExample)
CN (1) CN114761425A (enExample)
AU (1) AU2020363697B2 (enExample)
BR (1) BR112022006440A2 (enExample)
CA (1) CA3151781A1 (enExample)
IL (1) IL291924A (enExample)
MX (1) MX2022004080A (enExample)
WO (1) WO2021071962A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
GB202110363D0 (en) * 2021-07-19 2021-09-01 Celyad S A NKG2D CAR cells expressing IL-18 for adoptive cell therapy
KR20240043783A (ko) * 2021-08-06 2024-04-03 럿거스, 더 스테이트 유니버시티 오브 뉴 저지 유전자 변형 세포의 제조 방법
JP2024534981A (ja) * 2021-09-10 2024-09-26 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー 誘導ナチュラルキラー細胞の製造方法及びその使用
WO2023129937A1 (en) * 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
KR20250004622A (ko) 2022-04-08 2025-01-08 페이트 세러퓨틱스, 인코포레이티드 종양 표적화를 위한 키메라 항원 수용체
KR20250005097A (ko) * 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
WO2023215278A1 (en) * 2022-05-03 2023-11-09 The Broad Institute, Inc. Modified immune cells and methods for use thereof
JP2025516571A (ja) * 2022-05-10 2025-05-30 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫寛容を増強するための組成物及び方法
US20250090582A1 (en) * 2022-06-08 2025-03-20 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
CA3265025A1 (en) * 2022-08-17 2024-02-22 Artiva Biotherapeutics, Inc. METHODS FOR ADMINISTRATING NATURAL KILLER CELLS COMPRISING A CHIMERIC ANTIGENIC RECEPTOR (CAR) ANTI-HUMAN EPIDERMAL GROWTH FACTOR 2 (HER2)
WO2024140778A1 (zh) * 2022-12-27 2024-07-04 科济生物医药（上海）有限公司 Nkg2d工程化细胞及其组合物
WO2024159219A2 (en) * 2023-01-29 2024-08-02 Case Western Reserve University Chimeric antigen receptor constructs with optimized intracellular domains for natural killer cells
CN117285651B (zh) * 2023-09-27 2025-06-06 中国医学科学院北京协和医院 靶向c-MET的嵌合抗原受体、CAR-M及其用途
WO2025067318A1 (zh) * 2023-09-28 2025-04-03 沛尔生技医药股份有限公司 具有细胞内信号传导结构域及自然杀伤蛋白30跨膜结构域的核酸分子及包含其的嵌合抗原受体
WO2025097150A1 (en) * 2023-11-03 2025-05-08 The University Of Chicago Bcl-2 inhibition to amplify chimeric antigen receptor therapy
CN118420786B (zh) * 2024-06-12 2025-10-17 浙江大学医学院附属第一医院(浙江省第一医院) 一种靶向her2和hla-g的双特异性嵌合抗原受体及其应用
CN121227639A (zh) * 2024-06-28 2025-12-30 上海苹谱医疗科技有限公司 具有增强肿瘤靶向浸润能力的间充质干细胞及其应用
WO2026067758A1 (en) * 2024-09-29 2026-04-02 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113564A1 (en) * 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
EP3789487A1 (en) * 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
CN113862292B (zh) * 2015-01-29 2024-12-27 明尼苏达大学董事会 嵌合抗原受体、组合物以及方法
US12642852B1 (en) * 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
CN122146606A (zh) * 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
CN110035768A (zh) * 2016-07-26 2019-07-19 泰莎治疗私人有限公司 嵌合抗原受体
WO2018118494A2 (en) * 2016-12-22 2018-06-28 Xiaotong Song Use of car-modified human natural killer cells to treat cancer
US11578115B2 (en) * 2017-01-10 2023-02-14 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
EP3697809A1 (en) * 2017-10-20 2020-08-26 Institut Curie Dap10/12 based cars adapted for rush
US20200283501A1 (en) * 2017-10-26 2020-09-10 Regents Of The University Of Minnesota Recombinant immune cells, methods of making, and methods of use
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
BR112020011017A2 (pt) * 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
BR112020018049A2 (pt) * 2018-03-07 2020-12-29 Poseida Therapeutics, Inc. Composições de cartirina e métodos para uso
AU2019243315A1 (en) * 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof

Similar Documents

Publication Publication Date Title
JP2022541441A5 (enExample)
JP2022548943A5 (enExample)
JP2021505131A5 (enExample)
JP2022510207A5 (enExample)
US20240141041A1 (en) CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
JP2023549098A5 (enExample)
JP2021519061A5 (enExample)
JP2023505206A5 (enExample)
JP2023530704A5 (enExample)
JP2023548467A5 (enExample)
Bollino et al. Chimeric antigen receptor–engineered natural killer and natural killer T cells for cancer immunotherapy
JP2022109953A (ja) 細胞免疫療法のための方法および組成物
JP2022552314A5 (enExample)
JP2023548829A5 (enExample)
EP4148125A1 (en) Engineered immune cell for allotransplantation
JP2023545992A5 (enExample)
CN114761425A (zh) 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途
US10941202B2 (en) Isolated human mesenchymal stem cell expressing a bispecific antibody that binds CD33 and CD3 and method of using to treat cancer
RS62870B1 (sr) Himerni antigenski receptori sa ciljanim delovanjem na receptore spregnute sa g-proteinom i njihove upotrebe
JP2024533375A5 (enExample)
KR20210018838A (ko) 유전자 조작된 세포 및 응용
KR20230137923A (ko) 신규한 키메라 항원 수용체 및 이의 용도
AU2021338819A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
JP2024515920A5 (enExample)
JP2024525492A5 (enExample)